BioTav is in the process of evaluating the Newcastle Disease Virus (NDV) for the treatment of Glioblastoma. Current results of early-phase in vivo studies are already showing exciting results, with the combined therapy yielding significantly smaller tumor volumes and significantly longer median survival times.
Glioblastoma (GBM) is the most aggressive and common primary brain tumor in adults, with a median overall survival of 15 months. Tumor recurrence and poor prognosis are related to the tumorigenic cancer stem cells (CSCs), which drive resistance to therapies. The Newcastle Disease Virus, however, has been shown to selectively target and eliminate tumor cells, based on the presence of defective interferon signaling in tumor tissue. The effectiveness of different NDV strains and combinations was confirmed in seed material phase and is ready for clinical trials, to prove the oncolytic activity of NDV and its ability to treat glioma tumors.